Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results